FDA to Issue Decisions on Two Biotech Drugs This Week

The agency will rule on treatment expansions for Bristol Myers Squibb and Egetis Therapeutics by September 30.

Updated on Sept. 28, 2026 in Biotech

Bold flat-color editorial illustration of a glass vial on a flat background, representing federal regulatory oversight of pharmaceutical drugs. — The FDA is expected to reach regulatory decisions by September 30 regarding drug applications from Bristol Myers Squibb and Egetis Therapeutics. AI Illustration. Upload story photo >

Live Poll

Is now a good time to invest in pharmaceutical companies awaiting key FDA decisions?

The FDA is scheduled to finalize regulatory decisions this week for Egetis Therapeutics and Bristol Myers Squibb. These evaluations, set for September 28 and 30, follow a recent series of drug approvals for other pharmaceutical companies in the United States.

Why it matters

PDUFA dates serve as target deadlines for the FDA to complete drug application reviews, providing critical milestones for companies and their investors. These decisions determine whether new therapies or label expansions can enter the U.S. market.

Emcitate is currently approved for use in the European Union, while Camzyos is already FDA-approved for specific adults with symptomatic obstructive hypertrophic cardiomyopathy. Regulatory status for these treatments in the U.S. remains pending.

The players

Bristol Myers Squibb

This is a global biopharmaceutical company that develops medicines for serious diseases including cancer and cardiovascular conditions.

Egetis Therapeutics

This is a Swedish pharmaceutical company focused on developing therapies for rare diseases.

Scholar Rock

This is a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which signaling proteins play a fundamental role.

Biofrontera

This is an international biopharmaceutical company that specializes in the development and sale of dermatological drugs.

Mirum Pharmaceuticals

This is a biopharmaceutical company dedicated to the development and commercialization of therapies for rare liver diseases.

The details

The FDA will review Egetis Therapeutics' drug Emcitate on September 28 and Bristol Myers Squibb's expansion of Camzyos for adolescents with obstructive hypertrophic cardiomyopathy on September 30. Recent approvals include Scholar Rock's Isembyld, Biofrontera's Ameluz, and Mirum Pharmaceuticals' Atebrioz, which is expected to be available in the U.S. in October.

September 11, 2026: FDA approved Scholar Rock's Isembyld.
September 14, 2026: FDA approved Biofrontera's Ameluz label expansion.
September 25, 2026: FDA approved Mirum Pharmaceuticals' Atebrioz.
September 28, 2026: FDA decision date for Egetis Therapeutics' Emcitate.
September 30, 2026: FDA decision date for Bristol Myers Squibb's Camzyos.

Biotech
Sept. 25
FDA Approved Atebrioz for Rare Bone Disorder
Allergies
Sept. 28
FDA Approved First Therapy for MCT8 Deficiency
Heart Disease
Sept. 23
Acoramidis Reduced ATTR-CM Worsening Risk

The Tech Race

These upcoming regulatory decisions follow the standard Prescription Drug User Fee Act framework that dictates the pace of innovation and market entry for the pharmaceutical industry. The timing underscores how biotech firms rely on these milestone dates to transition from research to commercial availability.

The approval of new medications or label expansions can increase treatment options for patients suffering from specific rare or chronic diseases. For investors, these decisions often trigger significant volatility in the share prices of the pharmaceutical companies involved.

The takeaway

FDA regulatory decisions are pivotal events that define the operational future for pharmaceutical companies and the therapeutic landscape for patients. Stakeholders should monitor these dates as they often mark the shift from development to potential market access for new treatments.